Biotech Values

[iwfal]

MNTA -

frankly once i saw the bullish wording regarding no tlovenox and copaxone and the numbers started to make no sense i didn't read the piece closely

Am curious whether many/most/all of the analyst reviews of MNTA are of similar substance - 'hey, we think they'll continue as sole generic and get approval for g-copaxone, but we think the market psych will prevent any upside for quite a while.'

If a large number of the analyst reviews look of similar form then MNTA is an upside explosion just waiting to happen - there will be a chain reaction to get in as soon as there is a perception that the market psych has changed. But no one wants to be first.